Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Universal Ibogaine's enterprise value is $10.15 Mil.
Universal Ibogaine's EBITDA for the trailing twelve months (TTM) ended in Apr. 2025 was $-0.70 Mil. Therefore, Universal Ibogaine's EV-to-EBITDA for today is -14.48.
The historical rank and industry rank for Universal Ibogaine's EV-to-EBITDA or its related term are showing as below:
IBOGF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.35 Med: 0 Max: 0
Current: -14.48
IBOGF's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 12.31
vs IBOGF: -14.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Universal Ibogaine's PE Ratio (TTM) for today is calculated as:
Universal Ibogaine's share price for today is $0.02695.
Universal Ibogaine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Universal Ibogaine's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IBOGF vs LABT, CALC, LNAI: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Universal Ibogaine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universal Ibogaine EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Universal Ibogaine's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Universal Ibogaine's EV-to-EBITDA falls into.
Universal Ibogaine's current Enterprise Value is $10.15 Mil.
Universal Ibogaine's EBITDA for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universal Ibogaine (IBOGF) has a EV-to-EBITDA of -14.48 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Universal Ibogaine.
Is Universal Ibogaine's EV-to-EBITDA too high?
Universal Ibogaine's current EV-to-EBITDA is -14.48.
How does Universal Ibogaine's EV-to-EBITDA compare to LABT and CALC?
Universal Ibogaine's EV-to-EBITDA of -14.48 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 12.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.31, based on 397 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Universal Ibogaine. For the Biotechnology industry, the median EV-to-EBITDA is 12.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universal Ibogaine's current EV-to-EBITDA is -14.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current EV-to-EBITDA of -14.48. The current EV-to-EBITDA is -14.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current EV-to-EBITDA is -14.48 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBOGF has been successfully added to your 
